Brazil Cell And Gene Therapy Cdmo Market Size & Outlook
- HC Outsourcing
- CMO/CDMO
- Cell And Gene Therapy CDMO Market Outlook
- CMO/CDMO
Global Market
Related Markets
Ask a question about the cell and gene therapy cdmo market
Brazil cell and gene therapy cdmo market highlights
- The Brazil cell and gene therapy cdmo market generated a revenue of USD 67.4 million in 2024 and is expected to reach USD 370.2 million by 2033.
- The Brazil market is expected to grow at a CAGR of 21.2% from 2025 to 2033.
- In terms of segment, pre-clinical was the largest revenue generating phase in 2024.
- Pre-clinical is the most lucrative phase segment registering the fastest growth during the forecast period.
Cell and gene therapy cdmo market data book summary
| Market revenue in 2024 | USD 67.4 million |
| Market revenue in 2033 | USD 370.2 million |
| Growth rate | 21.2% (CAGR from 2025 to 2033) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
Other key industry trends
- In terms of revenue, Brazil accounted for 1.6% of the global cell and gene therapy cdmo market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Latin America, Brazil cell and gene therapy cdmo market is projected to lead the regional market in terms of revenue in 2033.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 370.2 million by 2033.
The robust growth & development in biologics and the rising biopharmaceutical market are expected to boost cell & gene therapy CDMO in the country. Moreover, the demand for cell and gene therapy CDMO in the country is growing as consumers increasingly seek effective biopharmaceutical formulations due to the growing burden of diseases.
The rising competition for drug development & approval is anticipated to increase the requirement for cell and gene therapy CDMO. Furthermore, government initiatives to reduce country’s pharmaceutical trade deficit and enhancement of domestic drug manufacturing are expected to boost the market.
For instance, in October 2023, Dipharma Francis S.R.L., a CDMO and major producer of APIs worldwide, announced that its manufacturing facility in Caronno Pertusella, close to Milan, Italy, has been granted the GMPcertification - Certificado de Boas Práticas de Fabricação (CBPF) - by Brazil's regulatory body Agência Nacional de Vigilância Sanitária (ANVISA). GMP certification from ANVISA enables Dipharma Francis S.R.L. to access the Brazilian pharmaceutical market, one of the largest in Latin America. This expands the company's market reach and potential client base
No credit card required*
Publish Date: Sep 08, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Samsung Electronics Co Ltd | View profile | 124,804 | 129, Samsung-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, Korea, Republic of, 443-742 | www.samsung.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| OmniAb Inc | View profile | 106 | 5980 Horton Street, Suite 600, Emeryville, CA, United States, 94608 | www.omniab.com |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| AGC Inc | View profile | 61,671 | 1-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan, 100-8405 | www.agc.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Rentschler Biopharma SE | View profile | 501-1000 | Laupheim, Baden-Wurttemberg, Germany, Europe | www.rentschler-biopharma.com |
Brazil Cell And Gene Therapy CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy CDMO Market Outlook will help companies and investors design strategic landscapes.
Pre-Clinical was the largest segment with a revenue share of 78.64% in 2024.
Horizon Databook has segmented the Brazil cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2021 to 2033.
The robust growth & development in biologics and the rising biopharmaceutical market are expected to boost cell & gene therapy CDMO in the country. Moreover, the demand for cell and gene therapy CDMO in the country is growing as consumers increasingly seek effective biopharmaceutical formulations due to the growing burden of diseases.
The rising competition for drug development & approval is anticipated to increase the requirement for cell and gene therapy CDMO. Furthermore, government initiatives to reduce country’s pharmaceutical trade deficit and enhancement of domestic drug manufacturing are expected to boost the market.
For instance, in October 2023, Dipharma Francis S.R.L., a CDMO and major producer of APIs worldwide, announced that its manufacturing facility in Caronno Pertusella, close to Milan, Italy, has been granted the GMPcertification - Certificado de Boas Práticas de Fabricação (CBPF) - by Brazil's regulatory body Agência Nacional de Vigilância Sanitária (ANVISA). GMP certification from ANVISA enables Dipharma Francis S.R.L. to access the Brazilian pharmaceutical market, one of the largest in Latin America. This expands the company's market reach and potential client base
- Brazil Cell And Gene Therapy Cdmo Market Phase Outlook (Revenue, USD Million , 2021-2033)
- Pre-clinical
- Clinical
- Brazil Cell And Gene Therapy Cdmo Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Rare Diseases
- Others
- Oncology
- Infectious Diseases
- Neurological disorders
- Brazil Cell And Gene Therapy Cdmo Market Product Type Outlook (Revenue, USD Million , 2021-2033)
- Gene Therapy
- Gene-Modified Cell Therapy
- Cell Therapy
Reasons to subscribe to Cell And Gene Therapy CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy CDMO Market Outlook databook
- Our clientele includes a mix of Cell And Gene Therapy CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil Cell And Gene Therapy CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Brazil Cell And Gene Therapy CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Brazil Cell And Gene Therapy Cdmo Market, 2021-2033 (US$M)
Brazil cell and gene therapy cdmo market statistics, by phase, 2021-2033 (US$M)
